PURPOSE: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent by ACS status and ACS subtype. METHODS: The COMBO collaboration (n = 3614) is a patient-level pooled dataset from the MASCOT and REMEDEE registries. We evaluated outcomes by ACS status, and ACS subtype in patients with ST segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) versus unstable angina (UA). The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Secondary outcomes included stent thrombosis (ST). RESULTS: We compared 1965 (54%) ACS and 1649 (46.0%) non-ACS patients. ACS presentations included 40% (n = 789) STEMI, 31% (n = 600) NSTEMI, and 29% (n = 576) UA patients. Risk of 1-year TLF was greater in ACS patients (4.5% vs. 3.3%, HR 1.51 95% CI 1.01-2.25, p = 0.045) without significant differences in definite/probable ST (1.1% vs 0.5%, HR 2.40, 95% CI 0.91-6.31, p = 0.08). One-year TLF was similar in STEMI, NSTEMI, and UA (4.8% vs 4.8% vs. 3.7%, p = 0.60), but definite/probable ST was higher in STEMI patients (1.9% vs 0.5% vs 0.7%, p = 0.03). Adjusted outcomes were not different in MI versus UA patients. CONCLUSIONS: Despite the novel EPC capture technology, COMBO stent PCI was associated with somewhat greater risk of 1-year TLF in ACS than in non-ACS patients, without significant differences in stent thrombosis. No differences were observed in 1-year TLF among ACS subtypes.
- MeSH
- akutní koronární syndrom klasifikace komplikace mortalita chirurgie MeSH
- časové faktory MeSH
- endoteliální progenitorové buňky metabolismus MeSH
- infarkt myokardu klasifikace komplikace MeSH
- koronární angioplastika metody MeSH
- koronární trombóza epidemiologie MeSH
- lidé MeSH
- nestabilní angina pectoris komplikace MeSH
- protézy - design MeSH
- rizikové faktory MeSH
- sirolimus aplikace a dávkování MeSH
- stenty uvolňující léky škodlivé účinky statistika a číselné údaje MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Klíčová slova
- apixaban,
- MeSH
- akutní koronární syndrom epidemiologie farmakoterapie mortalita MeSH
- antikoagulancia terapeutické užití MeSH
- Aspirin aplikace a dávkování MeSH
- cévní mozková příhoda epidemiologie MeSH
- fibrilace síní farmakoterapie MeSH
- fibrinolytika terapeutické užití MeSH
- hospitalizace statistika a číselné údaje MeSH
- klopidogrel aplikace a dávkování MeSH
- koronární trombóza epidemiologie MeSH
- krvácení chemicky indukované epidemiologie MeSH
- lidé MeSH
- prospektivní studie MeSH
- purinergní receptory P2Y - antagonisté aplikace a dávkování MeSH
- pyridiny aplikace a dávkování MeSH
- pyridony aplikace a dávkování MeSH
- senioři MeSH
- vitamin K antagonisté a inhibitory terapeutické užití MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- multicentrická studie MeSH
- novinové články MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Routine thrombus aspiration in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) does not improve clinical outcomes. However, there is remaining uncertainty about the potential benefit in those patients with high thrombus burden, where there is a biological rationale for greater benefit. OBJECTIVES: The purpose of this study was to evaluate the benefit of thrombus aspiration among STEMI patients with high thrombus burden. METHODS: TOTAL (ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI) was a randomized trial of routine manual thrombectomy versus PCI alone in patients with STEMI (n = 10,732). High thrombus burden (Thrombolysis In Myocardial Infarction thrombus grade ≥3) was a pre-specified subgroup. RESULTS: The primary outcome of cardiovascular (CV) death, MI, cardiogenic shock, or heart failure was not different at 1 year with thrombus aspiration in patients with high thrombus burden (8.1% vs. 8.3% thrombus aspiration; hazard ratio [HR]: 0.97; 95% confidence interval [CI]: 0.84 to 1.13) or low thrombus burden (6.0% vs. 5.0% thrombus aspiration; HR: 1.22; 95% CI: 0.73 to 2.05; interaction p = 0.41). However, among patients with high thrombus burden, stroke at 30 days was more frequent with thrombus aspiration (31 [0.7%] thrombus aspiration vs. 16 [0.4%] PCI alone, HR: 1.90; 95% CI: 1.04 to 3.48). In the high thrombus burden group, thrombus aspiration did not significantly improve CV mortality at 30 days (HR: 0.78; 95% CI: 0.61 to 1.01; p = 0.06) and at 1 year (HR: 0.88; 95% CI: 0.72 to 1.09; p = 0.25). Irrespective of treatment assignment, high thrombus burden was an independent predictor of death (HR: 1.78; 95% CI: 1.05 to 3.01). CONCLUSIONS: In patients with high thrombus burden, routine thrombus aspiration did not improve outcomes at 1 year and was associated with an increased rate of stroke. High thrombus burden is still an important predictor of outcome in STEMI. (A Trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI [TOTAL]; NCT01149044).
- MeSH
- cévní mozková příhoda epidemiologie MeSH
- infarkt myokardu s elevacemi ST úseků epidemiologie terapie MeSH
- kardiogenní šok epidemiologie MeSH
- koronární angioplastika * MeSH
- koronární trombóza epidemiologie terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- recidiva MeSH
- srdeční selhání epidemiologie MeSH
- trombektomie * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Prospektivní, randomizovaná, multicentrická studie ABSORB III posuzovala bezpečnost a účinnost everolimem potahované vstřebatelné podpory (BVS) na bázi poly-L-kyseliny mléčné (PLLA) Absorb® (Abbott, USA) v porovnání s everolimem potahovaným chrom-kobaltovým stentem (DES) Xience® (Abbott, USA) v průběhu jednoho roku po implantaci. Jednoroční výskyt primárního sledovaného ukazatele (srdeční smrt, IM v povodí cílové tepny, klinicky indikovaná revaskularizace cílové léze) prokázal noninferioritu BVS ve srovnání s DES, avšak s tendencí k vyššímu výskytu nežádoucích příhod v BVS větvi. Výsledky tříletého sledování pak prokázaly další nárůst výskytu nežádoucích událostí, statisticky významně trombóz stentu a akutního infarkt myokardu v povodí intervenované tepny u pacientů ošetřených BVS.
ABSORB III, a prospective, randomized, multicenter trial, evaluated the safety and efficacy of the Absorb® (Abbott, USA) everolimus-eluting poly-L-lactic acid based bioresorbable vascular scaffold (BVS) compared to the Xience® (Abbott, USA) everolimus-elutingcobalt-chromium stent (DES) during one year after implantation. One-year occurrence of the primary endpoint a composite ofcardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization) demonstrated noninferiorityof BVS compared to DES, however with a tendency to higher rates of adverse events in the BVS group. Three-year follow–upresults demonstrated an additional increase in adverse events occurence which was statistically, significant with respect to scaffoldthrombosis and target vessel myocardial infarction in the BVS group.
OBJECTIVE: To evaluate the long-term follow-up of the unrestricted use of a biodegradable polymer-coated drug-eluting stent in patients undergoing percutaneous coronary intervention (PCI). METHODS: The Nobori 2 study was a prospective, multicentre, observational registry evaluating the safety and the efficacy of the biodegradable polymer biolimus-eluting stent (BP-BES) among 3067 patients recruited at 125 international sites. The primary combined endpoint was a composite of cardiac death, myocardial infarction and target-lesion revascularisation (TLR). RESULTS: Five-year follow-up was available in 2738 (89.3%) patients. The combined endpoint occurred in 268 patients (10%, 95% CIs 8.9% to 11.3%) at 5 years, with 3.9% of events during the first year and 6.2% during years 1-5 of follow-up. Cumulative rates of TLR and definite/probable stent thrombosis were 5.3% (95% CI 4.5% to 6.3%) and 1.1% (95% CI 0.8% to 1.6%), respectively. Between 1 and 5 years, TLR and very late stent thrombosis rates were 3.5% (95% CI 2.8% to 4.4%) and 0.6% (95% CI 0.3% to 1.1%), respectively. Previous PCI (HR, 2.05, 95% CI 1.68 to 2.50), moderate-to-severe renal disease (HR, 1.89, 95% CI 1.30 to 2.74) and peripheral vascular disease (HR, 1.86, 95% CI 1.38 to 2.52) were the three most powerful independent predictors of the combined endpoint at 5 years. CONCLUSIONS: The final 5-year follow-up of the Nobori 2 registry demonstrates the safety and effectiveness of the BP-BES in an unselected, broadly inclusive cohort of PCI patients, highlighting the excellent performance of this coronary stent technology after polymer biodegradation. TRIAL REGISTRATION NUMBER: ISRCTN81649913; Results.
- MeSH
- imunosupresiva aplikace a dávkování MeSH
- Kaplanův-Meierův odhad MeSH
- koronární angioplastika škodlivé účinky přístrojové vybavení metody MeSH
- koronární trombóza epidemiologie etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- nemoci ledvin epidemiologie etiologie MeSH
- onemocnění periferních cév epidemiologie etiologie MeSH
- opakovaná terapie statistika a číselné údaje MeSH
- polymery MeSH
- prospektivní studie MeSH
- protézy - design MeSH
- registrace MeSH
- senioři MeSH
- sirolimus aplikace a dávkování analogy a deriváty MeSH
- stenty uvolňující léky * škodlivé účinky MeSH
- vstřebatelné implantáty * škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
BACKGROUND: Stent thrombosis (ST) is a serious complication following coronary stenting. Intravascular optical coherence tomography (OCT) may provide insights into mechanistic processes leading to ST. We performed a prospective, multicenter study to evaluate OCT findings in patients with ST. METHODS: Consecutive patients presenting with ST were prospectively enrolled in a registry by using a centralized telephone registration system. After angiographic confirmation of ST, OCT imaging of the culprit vessel was performed with frequency domain OCT. Clinical data were collected according to a standardized protocol. OCT acquisitions were analyzed at a core laboratory. Dominant and contributing findings were adjudicated by an imaging adjudication committee. RESULTS: Two hundred thirty-one patients presenting with ST underwent OCT imaging; 14 (6.1%) had image quality precluding further analysis. Of the remaining patients, 62 (28.6%) and 155 (71.4%) presented with early and late/very late ST, respectively. The underlying stent type was a new-generation drug-eluting stent in 50.3%. Mean reference vessel diameter was 2.9±0.6 mm and mean reference vessel area was 6.8±2.6 mm2. Stent underexpansion (stent expansion index <0.8) was observed in 44.4% of patients. The predicted average probability (95% confidence interval) that any frame had uncovered (or thrombus-covered) struts was 99.3% (96.1-99.9), 96.6% (92.4-98.5), 34.3% (15.0-60.7), and 9.6% (6.2-14.5) and malapposed struts was 21.8% (8.4-45.6), 8.5% (4.6-15.3), 6.7% (2.5-16.3), and 2.0% (1.2-3.3) for acute, subacute, late, and very late ST, respectively. The most common dominant finding adjudicated for acute ST was uncovered struts (66.7% of cases); for subacute ST, the most common dominant finding was uncovered struts (61.7%) and underexpansion (25.5%); for late ST, the most common dominant finding was uncovered struts (33.3%) and severe restenosis (19.1%); and for very late ST, the most common dominant finding was neoatherosclerosis (31.3%) and uncovered struts (20.2%). In patients presenting very late ST, uncovered stent struts were a common dominant finding in drug-eluting stents, and neoatherosclerosis was a common dominant finding in bare metal stents. CONCLUSIONS: In patients with ST, uncovered and malapposed struts were frequently observed with the incidence of both decreasing with longer time intervals between stent implantation and presentation. The most frequent dominant observation varied according to time intervals from index stenting: uncovered struts and underexpansion in acute/subacute ST and neoatherosclerosis and uncovered struts in late/very late ST.
- MeSH
- koronární angioplastika škodlivé účinky trendy MeSH
- koronární trombóza diagnostické zobrazování epidemiologie prevence a kontrola MeSH
- lidé MeSH
- optická koherentní tomografie metody trendy MeSH
- prospektivní studie MeSH
- registrace MeSH
- senioři MeSH
- stenty uvolňující léky škodlivé účinky trendy MeSH
- výzkumná zpráva trendy MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
Úvod: Cévní mozková příhoda (CMP) patří mezi hlavní příčiny morbidity i mortality celosvětově. V České republice v roce 2012 bylo cévní onemocnění mozku přímou příčinou 10 % všech úmrtí. Cíl: Cílem naší práce bylo zhodnocení nálezů z jícnové echokardiografie (TEE) u pacientů s podezřením na kardioembolickou CMP či transitorní ischemickou ataku (TIA), kteří byli indikováni k provedení tohoto vyšetření v naší echokardiografické laboratoři. Metodika: V období od července 2009 do března 2013 (tj. v průběhu 45 měsíců) bylo v naší echokardiografické laboratoři provedeno 95 TEE indikovaných pro ischemickou CMP či TIA. Sledovali jsme výskyt patologických nálezů, které mají dle literatury kardioembolický potenciál. Výsledky: Desetkrát bylo vyšetření provedeno pro podezření na infekční endokarditidu, ta byla potvrzena ve třech případech. Pět nemocných bylo nositelem mechanické chlopenní protézy, ani v jednom případě nebyla zjištěna její dysfunkce. U ostatních nemocných bylo nejčastějším nálezem foramen ovale patens (30 nemocných, tj. 37 %), ve třech případech se vyskytovalo současně s aneurysmatem septa síní. U tří nemocných jsme našli hemodynamicky málo významný defekt septa síní, u dvou přítomnost nitrosrdečního trombu. Dilatace levé síně a porušená systolická funkce ouška levé síně může souviset s výskytem fibrilace síní. Objem levé síně byl stanoven v 86 případech, pouze 35 pacientů (tj. 40,7 %) mělo objem levé síně normální. Patologie, která může být dána do souvislosti s proběhlou mozkovou ischemií, byla zjištěna u 56 % nemocných. Závěr: Jícnová echokardiografie je suverénní metodou k vyšetření případných zdrojů kardioembolizace. V našem souboru byla u nadpoloviční většiny nemocných nalezena patologie, která mohla souviset s prodělanou mozkovou ischemií a v 17 případech z celkového počtu 95 nemocných (tj. v 18 %) vedl nález ke změně strategie léčby.
Introduction: The cerebrovascular accident ranks among the main causes of mortality and morbidity worldwide. In the Czech Republic, the cerebrovascular disease was the direct cause of the death in 10% of the cases of death in the year 2012 (Healthcare Annual CZ 2012). Aim: The aim of our study was to evaluate the transoesophageal echocardiogram findings (TOE) in patients with suspicion for cardioembolic stroke or TIA who were indicated to this examination in our echocardiography laboratory. Methodology: During the period from July 2009 to March 2013 (45 months), 108 TOE had been realized in our echocardiographic laboratory that was indicated for ischemic stroke or TIA. We monitored the occurrence of pathological findings that have the cardioembolic potential according to the literature. Results: The examination was performed for a suspect of an infective endocarditis 10 times, this was proven in 3 cases. 5 patients were holders of a mechanical valvular prosthesis, its dysfunction was discovered in neither case. The most frequent diagnosis was foramen ovale patens in the other patients (30 patients, i.e. 37%), in 3 cases it occurred simultaneously with an atrial septal aneurysm. We found a haemodynamic little significant atrial septal defect in 3 patients, a presence of an endocardial thrombus in 2 patients. A left atrial dilation and a systolic dysfunction of a left atrium auricle can relate with an occurrence of an atrial fibrillation. A left atrium volume was determined in 86 cases, only 35 patients (i.e. 40.7%) have the normal left atrium volume. A pathology, which can be connected with a cerebral ischemia that took place, was found in 56% of the patients. Conclusion: Transoesophageal echocardiography is an independent method in examination of potential sources of cardioembolism. In our sample, a pathology in more than half of the patients was diagnosed that could refer to a suffered ischemic stroke and the diagnosis led to a change in a treatment strategy in 17 cases of the total number of 95 patients (i.e. at 18%).
- MeSH
- bakteriální endokarditida epidemiologie komplikace ultrasonografie MeSH
- cévní mozková příhoda * diagnóza etiologie MeSH
- diferenciální diagnóza MeSH
- dysfunkce levé srdeční komory epidemiologie komplikace ultrasonografie MeSH
- echokardiografie transezofageální * metody MeSH
- fibrilace síní epidemiologie komplikace ultrasonografie MeSH
- foramen ovale apertum epidemiologie komplikace ultrasonografie MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- koronární trombóza epidemiologie komplikace ultrasonografie MeSH
- lidé MeSH
- tranzitorní ischemická ataka * diagnóza etiologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
The aim of the present study was to investigate the prevalence of left ventricular (LV) thrombus formation and important determinants in patients with acute ST elevation myocardial infarction localized to the anterior wall treated with percutaneous coronary intervention (PCI) and dual-antiplatelet therapy. One hundred selected patients with ST elevation myocardial infarctions revascularized with PCI in the left anterior descending coronary artery were included. The patients participated in the Autologous Stem Cell Transplantation in Acute Myocardial Infarction (ASTAMI) trial. All were treated with aspirin 75 mg/day and clopidogrel 75 mg/day and underwent serial echocardiography and magnetic resonance imaging during the first 3 months after PCI. After 4 to 5 days, the ejection fraction and infarct size in percentage of the left anterior descending coronary artery area were assessed using single photon-emission computed tomography in addition to the ejection fraction by echocardiography. LV thrombi were detected in 15 patients during the first 3 months, 2/3 of them within the first week. No differences in baseline characteristics between the groups with and without LV thrombi were shown. However, in the thrombus group, significantly higher peak creatine kinase levels (6,128 vs 2,197 U/L, p <0.01), larger infarct sizes (82.5% vs 63.8%, p <0.01), and lower ejection fractions on single photon-emission computed tomography (35.5% vs 40.0%, p = 0.03) and on echocardiography (43.0% vs 46.0%, p = 0.03) were found compared to patients without LV thrombi. In conclusion, LV thrombus formation is a frequent finding in patients with anterior wall ST elevation myocardial infarction treated acutely with PCI and dual-antiplatelet therapy and should be assessed by echocardiography within the first week.
- MeSH
- Aspirin aplikace a dávkování terapeutické užití MeSH
- balónková koronární angioplastika MeSH
- echokardiografie MeSH
- infarkt myokardu patologie terapie MeSH
- inhibitory agregace trombocytů aplikace a dávkování terapeutické užití MeSH
- jednofotonová emisní výpočetní tomografie MeSH
- kombinovaná terapie MeSH
- koronární trombóza diagnóza epidemiologie MeSH
- kreatinkinasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- neparametrická statistika MeSH
- prevalence MeSH
- rozdělení chí kvadrát MeSH
- senioři MeSH
- srdeční komory patologie MeSH
- stenty MeSH
- tiklopidin analogy a deriváty aplikace a dávkování terapeutické užití MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
The aim of this study was to evaluate the long-term clinical outcome of the efficacy and safety of sirolimus-eluting stents (SES) for in-stent restenosis (ISR) in the TRUE (Tuscany Registry of Unselected In-Stent Restenosis) database. BACKGROUND: The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months. Clinical outcome at 4 years is reported. METHODS: A total of 244 patients with ISR who were treated with SES implantation represent the study population. The incidence of major adverse cardiac events was collected at 4 years. RESULTS: At 4-year follow-up, overall mortality was 9.8% (24 patients). Cardiac death occurred in 11 (4.5%), nonfatal myocardial infarction in 8 (3.2%), and TLR in 27 (11.1%) patients for a cumulative event-free survival rate of 80.3%. Definite stent thrombosis occurred in 5 (2%) patients and possible stent thrombosis in 2 (0.8%). Diabetes remained an independent negative predictor of freedom from TLR (odds ratio [OR]: 0.38; 95% confidence interval [CI]: 0.20 to 0.71, p = 0.002) and major adverse cardiac events (OR: 0.38; 95% CI: 0.20 to 0.71, p = 0.002). CONCLUSIONS: The clinical benefit of SES implantation for bare-metal stent ISR is maintained at 4 years with a low TLR rate and an overall incidence of stent thrombosis of 0.7% per year.
- MeSH
- Aspirin terapeutické užití MeSH
- diabetes mellitus epidemiologie MeSH
- infarkt myokardu epidemiologie MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- kardiovaskulární látky aplikace a dávkování MeSH
- koronární restenóza epidemiologie terapie MeSH
- koronární trombóza epidemiologie MeSH
- kreatinin analýza MeSH
- lidé MeSH
- následné studie MeSH
- prospektivní studie MeSH
- registrace MeSH
- revaskularizace myokardu statistika a číselné údaje MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sirolimus aplikace a dávkování MeSH
- stenty uvolňující léky MeSH
- tepový objem MeSH
- tiklopidin analogy a deriváty terapeutické užití MeSH
- Check Tag
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
Concern regarding risk of late thrombosis after "off-label" treatment with drug-eluting stents has prompted increased use of bare-metal stents (BMS) in current practice. The sequelae of late BMS failures, however, have been poorly characterized. METHODS AND RESULTS: We performed a retrospective study of 4503 consecutive patients treated with at least 1 BMS and dual antiplatelet therapy between 1994 and 2000. The cumulative incidence of stent thrombosis was 0.5% at 30 days (95% CI, 0.3% to 0.7%), 0.8% at 1 year (95% CI, 0.6% to 1.1%), and 2.0% at 10 years (95% CI, 1.5% to 2.5%). Risk of late (30 days to 1 year) and very late (>1 year) BMS thrombosis was increased among patients considered off label for drug-eluting stent use (P=0.024). When saphenous vein graft interventions were excluded, however, risk after off-label use was not significantly increased (P=0.23). Other correlates included vein graft intervention, prior myocardial infarction (MI), peripheral vascular disease, and ulcerated lesion (P<0.001). Mortality was markedly increased after late and very late BMS thrombosis, particularly during the first 30 days (hazard ratios, 22 [95% CI, 3.1 to 159] and 40 [95% CI, 15 to 107], respectively). The 10-year incidence of clinical restenosis was 18.1% (95% CI, 16.5% to 19.7%), presenting with MI in 2.1% (95% CI, 1.6% to 2.6%). Restenosis presenting with MI was associated with increased mortality compared with no restenosis (hazard ratio, 2.37; P<0.001) and with restenosis with a non-MI presentation (hazard ratio, 2.42; P<0.001). CONCLUSIONS: The incidence of BMS thrombosis and of MI caused by restenosis during extended follow-up is significant. Both complications are associated with mortality.
- MeSH
- balónková koronární angioplastika škodlivé účinky trendy MeSH
- časové faktory MeSH
- kohortové studie MeSH
- koronární restenóza epidemiologie etiologie mortalita MeSH
- koronární trombóza epidemiologie etiologie mortalita MeSH
- kovy škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- retrospektivní studie MeSH
- senioři MeSH
- stenty škodlivé účinky trendy MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
